Site Announcement
For the latest results and update on CytoDyn’s Phase 2 CRC trial and more, here’s a link to our April 30, 2026 investor update webinar
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 05/11/26 | D | Notice of Exempt Offering of Securities |
|
5 | |
| 04/30/26 | 8-K | Current report |
|
  |
27 |
| 04/22/26 | S-1 | General form for registration of securities under the Securities Act of 1933 |
|
|
156 |
| 04/08/26 | 424B3 | Prospectus [Rule 424(b)(3)] |
|
35 | |
| 04/08/26 | 10-Q | Quarterly report [Sections 13 or 15(d)] |
|
|
47 |
| 03/25/26 | 424B3 | Prospectus [Rule 424(b)(3)] |
|
4 | |
| 03/24/26 | 4 | Statement of changes in beneficial ownership of securities |
|
1 | |
| 03/24/26 | 4 | Statement of changes in beneficial ownership of securities |
|
1 | |
| 03/24/26 | 4 | Statement of changes in beneficial ownership of securities |
|
1 | |
| 03/24/26 | 4 | Statement of changes in beneficial ownership of securities |
|
1 |
